ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
Authors:
- Francesca RuzziFRFrancesca Ruzzi
- Stefania AngelicolaSAStefania Angelicola
- Lorena LanduzziLLLorena Landuzzi
- Elena NironiENElena Nironi
- Maria Sofia SempriniMSMaria Sofia Semprini
- Laura ScalambraLSLaura Scalambra
- Annalisa AltimariAAAnnalisa Altimari
- Elisa GruppioniEGElisa Gruppioni
- Michelangelo FiorentinoMFMichelangelo Fiorentino
- Francesca GiunchiFGFrancesca Giunchi
- Manuela FerracinMFManuela Ferracin
- Annalisa AstolfiAnnalisa Astolfi
Open Access
- 1 November 2022
- journal article
- research article
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 11 (11) , 2216-2229
Abstract
Original Article ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC Francesca Ruzzi, Stefania Angelicola, Lorena Landuzzi, Elena Nironi, Maria So a Semprini, Laura Scalambra, Annalisa Altimari, Elisa Gruppioni, Michelangelo Fiorentino, Francesca Giunchi, Manuela Ferracin, Annalisa Astol, Valentina Indio, Andrea Ardizzoni, Francesco Gelsomino, Patrizia Nanni, Pier-Luigi Lollini, Arianna PalladiniKeywords
This publication has 38 references indexed in Scilit:
- An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung CancerJournal of Thoracic Oncology, 2016
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung CancerNew England Journal of Medicine, 2014
- Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung CancerPLOS ONE, 2013
- Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung CancerClinical Cancer Research, 2012
- Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung CancerJournal of Thoracic Oncology, 2012
- Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K InhibitorPLOS ONE, 2012
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Ba/F3 cells and their use in kinase drug discoveryCurrent Opinion in Oncology, 2007
- The protein tyrosine kinase family of the human genomeOncogene, 2000